CEO Vipin Garg highlighted the imminent readout of the IMPACT Phase 2b NASH trial, stating "we are confident of achieving the trial’s key efficacy and safety objectives" and emphasized that if ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback